Literature DB >> 23482326

MitraClip® via direct right atrial access in case of a missing inferior vena cava.

Christian Frerker1, Felix Meincke, Hans-Peter Seibert, Hannes Alessandrini, Felix Kreidel, Michael Caspary, Cord Busse, Ulrich Schäfer, Karl-Heinz Kuck.   

Abstract

The presence of mitral regurgitation (MR) in patients with heart failure represents an independent predictor of mortality. Until now, the standard therapy for severe MR has been cardiac surgery in order to perform mitral valve replacement or mitral valve repair. With the introduction of the MitraClip® system (Abbott Vascular - Structural Heart, Menlo Park, CA, USA) in 2008, there is now an alternative percutaneous treatment option available for high-risk patients. We report on an 84-year-old male patient who was admitted to the emergency room with increasing shortness of breath due to severe functional MR, at stage NYHA III. In the following days the patient developed cardiogenic shock due to failure of the diuretic medication. The case first described here demonstrates an alternative transseptal route of access via a direct atrial puncture of the RA in a patient with absent inferior vena cava. This approach was successfully used to perform a MitraClip® procedure in this patient with functional MR and cardiogenic shock. It was possible to treat mitral regurgitation and the consecutive cardiogenic shock by implanting two MitraClips®.

Entities:  

Mesh:

Year:  2013        PMID: 23482326     DOI: 10.4244/EIJV9I5A102

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  2 in total

1.  MitraClip Deployed via Left Femoral Vein in an 85-Year-Old Woman with Mitral Regurgitation.

Authors:  Mohan Mallikarjuna Rao Edupuganti; Deniz Mutlu; David M Mego; Kostas Marmagkiolis; Mehmet Cilingiroglu
Journal:  Tex Heart Inst J       Date:  2019-06-01

Review 2.  [Mitral valve interventions: Where do we stand?].

Authors:  C Frerker; T Schmidt; F Kreidel; M Schlüter; K-H Kuck
Journal:  Herz       Date:  2015-08       Impact factor: 1.443

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.